XXXX in childhood and adolescence.

@entity1 @entity2847 @entity2013 @entity6726 @entity146 @entity5 @entity10 @entity1866 @entity4614 @entity977 @entity652
A clinicopathological study of 56 pediatric @entity1 with non-ACTH-secreting @entity977 removed by a transsphenoidal neurosurgical approach was undertaken to better define the clinical presentation, to assess demographic factors, to determine the immunohistochemical staining characteristics of the @entity5 , and to evaluate the outcome of transsphenoidal surgical treatment and other adjuvant therapies. A separate analysis of @entity2013 @entity1 was performed. All @entity5 were confirmed histologically and immunophenotyped for pituitary hormones. Forty-one @entity1 had @entity5 that stained for PRL alone, eight @entity1 had @entity5 that stained for PRL and GH, six @entity1 had @entity652 , and one @entity1 had a @entity5 that stained for glycoprotein hormones. No @entity5 contained GH alone. Macroadenomas exceeded microadenomas (1.4:1). There were no male @entity1 with microadenomas of any type. Females outnumbered males (3.3:1). @entity1 presented most frequently with @entity10 , @entity1866 (in females), @entity6726 , and @entity4614 . All but one of the @entity1 with @entity4614 at presentation had macroadenomas. @entity5 staining characteristics did not always correlate well with clinical status, especially with regard to GH-containing @entity5 . Pediatric @entity977 did not appear to be more invasive or more @entity146 than adult @entity977 , contrary to some previous reports. The @entity1 with microadenomas had a 70% operative cure rate and a 65% long term cure rate; the recurrence rate for microadenoma @entity1 was 25%. Macroadenoma @entity1 had a 33% operative cure rate, a 55% long term cure rate, and a recurrence rate of 33%. Thus, microadenoma and macroadenoma @entity1 had similar long term cure rates, but macroadenoma @entity1 required more @entity146 adjuvant therapy (second surgery, radiation, or @entity2847 ) and had higher rates of @entity4614 (52% of macroadenoma @entity1 vs. 0% of microadenoma @entity1 required long term hormone replacement).
